Single- and Multiple-dose Pharmacokinetics of Biphasic Immediate-release/extended-release Hydrocodone Bitartrate/acetaminophen (MNK-155) Compared with Immediate-release Hydrocodone Bitartrate/ibuprofen and Immediate-release Tramadol HCl/acetaminophen

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2015 Oct 29

PMID 26508885

Authors

Krishna Devarakonda

Kenneth Kostenbader

Michael J Giuliani

Jim L Young

Affiliations

Soon will be listed here.

Abstract

Objective: To characterize the single-dose and steady-state pharmacokinetics (PK) of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (IR/ER HB/APAP), IR HB/ibuprofen, and IR tramadol HCl/APAP.

Methods: In this single-center, open-label, randomized, four-period crossover study, healthy participants received four treatments under fasted conditions: 1) a single dose of two IR/ER HB/APAP 7.5/325 mg tablets (15/650 mg total dose) on day 1, followed by two tablets every 12 hours (q12h) beginning on day 3; 2) a single dose of IR HB/ibuprofen 15/400 mg (divided as one 7.5/200 mg tablet at hour 0 and 6), followed by one tablet every 6 hours (q6h) beginning on day 3; 3) a single dose of IR tramadol HCl/APAP 75/650 mg (divided as one 37.5/325 mg tablet at hour 0 and 6), followed by one tablet q6h beginning on day 3; and 4) a single dose of three IR/ER HB/APAP 7.5/325 mg tablets (22.5/975 mg total dose) on day 1, a three-tablet initial dose at 48 hours followed by two-tablet doses q12h beginning on day 3. Hydrocodone and APAP single-dose and steady-state PK were assessed. Adverse events were monitored.

Results: The PK analysis was carried out on 29 of 48 enrolled participants who completed all treatment periods. Single-dose hydrocodone exposure was similar for IR/ER HB/APAP 22.5/975 mg and IR HB/ibuprofen 15/400 mg; time to maximum observed plasma concentration was shorter and half-life was longer for IR/ER HB/APAP (22.5/975 mg and 15/650 mg) vs IR HB/ibuprofen. Single-dose APAP exposure was similar for IR/ER HB/APAP 15/650 mg and IR tramadol HCl/APAP 75/650 mg. Steady-state hydrocodone and APAP exposures were similar between treatments. Adverse events were similar for each treatment and typical of low-dose combination opioid analgesics. With dosing q12h, IR/ER HB/APAP had half as many concentration peaks and troughs as the comparators treated q6h.

Conclusion: With dosing q12h, IR/ER HB/APAP provided similar peak and total steady-state hydrocodone and APAP exposure vs IR comparators.

References

Bourne M, Rosenthal N, Xiang J, Jordan D, Kamin M . Tramadol/acetaminophen tablets in the treatment of postsurgical orthopedic pain. Am J Orthop (Belle Mead NJ). 2006; 34(12):592-7. View

Chang D, Desjardins P, Bird S, Black P, Chen E, Petruschke R . Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin. 2004; 20(6):939-49. DOI: 10.1185/030079904125003863. View

WAIFE S, Gruber Jr C, Rodda B, Nash J . Problems and solutions to single-dose testing of analgesics: comparison of propoxyphene, codeine, and fenoprofen. Int J Clin Pharmacol Biopharm. 1975; 12(1-2):301-4. View

Hewitt D, Todd K, Xiang J, Jordan D, Rosenthal N . Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: a randomized, placebo-controlled trial. Ann Emerg Med. 2006; 49(4):468-80, 480.e1-2. DOI: 10.1016/j.annemergmed.2006.08.030. View

Chang D, Desjardins P, King T, Erb T, Geba G . The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial. Anesth Analg. 2004; 99(3):807-815. DOI: 10.1213/01.ANE.0000133141.75831.57. View

. Schedule of controlled substances: placement of tramadol into schedule IV. Final rule. Fed Regist. 2014; 79(127):37623-30. View

Chou R, Fanciullo G, Fine P, Adler J, Ballantyne J, Davies P . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113-30. PMC: 4043401. DOI: 10.1016/j.jpain.2008.10.008. View

Devarakonda K, Morton T, Margulis R, Giuliani M, Barrett T . Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions. Drug Des Devel Ther. 2014; 8:1125-34. PMC: 4145823. DOI: 10.2147/DDDT.S64261. View

McCarberg B, Barkin R . Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001; 8(3):181-6. DOI: 10.1097/00045391-200105000-00006. View

10.

Hippisley-Cox J, Coupland C, Logan R . Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 331(7528):1310-6. PMC: 1298853. DOI: 10.1136/bmj.331.7528.1310. View

11.

Palangio M, Morris E, Doyle Jr R, Dornseif B, Valente T . Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Clin Ther. 2002; 24(1):87-99. DOI: 10.1016/s0149-2918(02)85007-x. View

12.

Raffa R, Tallarida R, Taylor Jr R, Pergolizzi Jr J . Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother. 2012; 13(9):1261-70. DOI: 10.1517/14656566.2012.668531. View

13.

BEAVER W . Combination analgesics. Am J Med. 1984; 77(3A):38-53. DOI: 10.1016/s0002-9343(84)80101-1. View

14.

de Leon-Casasola O . A review of the literature on multiple factors involved in postoperative pain course and duration. Postgrad Med. 2014; 126(4):42-52. DOI: 10.3810/pgm.2014.07.2782. View

15.

Raffa R . Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther. 2001; 26(4):257-64. DOI: 10.1046/j.1365-2710.2001.00355.x. View

16.

Marco C, Plewa M, Buderer N, Black C, Roberts A . Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial. Acad Emerg Med. 2005; 12(4):282-8. DOI: 10.1197/j.aem.2004.12.005. View

17.

Pedersen L, Borchgrevink P, Riphagen I, Fredheim O . Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review. Acta Anaesthesiol Scand. 2014; 58(4):390-401. DOI: 10.1111/aas.12279. View

18.

Argoff C, Silvershein D . A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009; 84(7):602-12. PMC: 2704132. DOI: 10.1016/S0025-6196(11)60749-0. View

19.

Litkowski L, Christensen S, Adamson D, Van Dyke T, Han S, Newman K . Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized,.... Clin Ther. 2005; 27(4):418-29. DOI: 10.1016/j.clinthera.2005.04.010. View

20.

. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule. Fed Regist. 2014; 79(163):49661-82. View